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Abstract
The improved characterisation of risk factors for rheumatoid arthritis (RA) suggests they could be combined to identify
individuals at increased disease risks in whom preventive strategies may be evaluated. We aimed to develop an RA
prediction model capable of generating clinically relevant predictive data and to determine if it better predicted younger
onset RA (YORA). Our novel modelling approach combined odds ratios for 15 four-digit/10 two-digit HLA-DRB1 alleles, 31
single nucleotide polymorphisms (SNPs) and ever-smoking status in males to determine risk using computer simulation and
confidence interval based risk categorisation. Only males were evaluated in our models incorporating smoking as ever-
smoking is a significant risk factor for RA in men but not women. We developed multiple models to evaluate each risk
factor’s impact on prediction. Each model’s ability to discriminate anti-citrullinated protein antibody (ACPA)-positive RA
from controls was evaluated in two cohorts: Wellcome Trust Case Control Consortium (WTCCC: 1,516 cases; 1,647 controls);
UK RA Genetics Group Consortium (UKRAGG: 2,623 cases; 1,500 controls). HLA and smoking provided strongest prediction
with good discrimination evidenced by an HLA-smoking model area under the curve (AUC) value of 0.813 in both WTCCC
and UKRAGG. SNPs provided minimal prediction (AUC 0.660 WTCCC/0.617 UKRAGG). Whilst high individual risks were
identified, with some cases having estimated lifetime risks of 86%, only a minority overall had substantially increased odds
for RA. High risks from the HLA model were associated with YORA (P,0.0001); ever-smoking associated with older onset
disease. This latter finding suggests smoking’s impact on RA risk manifests later in life. Our modelling demonstrates that
combining risk factors provides clinically informative RA prediction; additionally HLA and smoking status can be used to
predict the risk of younger and older onset RA, respectively.
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Introduction
Rheumatoid arthritis (RA) is a common chronic inflammatory
disorder. It results in substantial morbidity and disability alongside
high medical and societal costs [1], [2]. There is therefore growing
interest in preventing its development. Such prevention requires
an ability to reliably predict who will develop RA. Advances in
characterising genetic and environmental risk factors for RA
together with developments in modelling methodology make
predicting its development a realistic possibility.
RA is a clinical syndrome spanning multiple subsets [3]. The
commonest subdivision is by the presence or absence of
rheumatoid factor (RF)/anti-citrullinated protein antibodies
(ACPA), termed seropositive and seronegative RA respectively.
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Risk factor evaluation has mainly focussed on seropositive RA with
nearly half its genetic architecture known. HLA-DRB1 alleles, in
particular those encoding the shared epitope, dominate genetic
risk accounting for approximately 36% of heritability [4]; 45 non-
HLA variants explain approximately 15% of heritability [4].
Smoking is the main environmental risk factor [5]; it predisposes
to seropositive RA and has a synergistic relationship with the
shared epitope [6], [7]. Although single factors do not provide
sufficient risk stratification, combining multiple factors within a
prediction model may identify clinically relevant high- and low-
risk groups. The large risks conferred by HLA make such
modelling an attractive prospect in RA despite limited success in
other complex disorders [8–10].
RA develops over many years prior to clinical presentation [11].
Initially, individuals with genetic susceptibility variants are
exposed to environmental risks; some may develop autoantibodies
(RF/ACPA) [12]. A proportion will subsequently develop
arthralgia, which may progress to an unclassified arthritis followed
by a fully expressed RA phenotype. Pilot studies in unclassified
arthritis indicate that secondary prevention may be possible with
corticosteroids [13], [14], methotrexate [15] and biologics [16]
attenuating the progression to RA. Although preventive treat-
ments may be more effective before immune dysregulation and
symptoms develop, primary prevention is not currently possible as
no reliable method exists to identify asymptomatic high-risk
individuals.
Prevention is likely to have a larger impact in younger onset RA
(YORA) due to the increased health costs associated with a longer
disease duration [17]. Genetic susceptibility factors may influence
RA’s age of onset with HLA-DRB1*04 alleles [18–21] and multiple
single nucleotide polymorphisms (SNPs) such as those tagging
VEGFA [22], RANKL [19], [23], MMP1-3 [22] and PTPN22 [24],
[25] loci associating with YORA.
One group has published two reports outlining predictive
models for RA. Their models, built using 8 HLA alleles, 14–31
SNPs and clinical factors, generated an aggregate weighted genetic
risk score (wGRS) formed from the product of individual-locus
odds ratios (ORs) [26], [27]. They were reasonably accurate at
determining disease status in approximately 1,200 cases and 1,200
controls, with a maximal area under the curve (AUC) of 0.752.
They also demonstrated a better ability to predict erosive RA (a
more severe phenotype). However, only a minority of the studied
populations had significantly elevated risks for RA.
We report an alternative modelling approach to predicting RA.
Our novel modelling method uses computer simulation to
categorise risk profiles; our models also incorporate a larger
number of HLA risk variants. The risk factors included in our
modelling comprise 15 four-digit/10 two-digit HLA-DRB1 alleles,
31 SNPs and male ever-smoking status (as ever-smoking is a
significant risk for RA in males only). We applied our models to
two large cohorts of European ancestry: the Wellcome Trust Case
Control Consortium (WTCCC) and the UK RA Genetics Group
(UKRAGG) Consortium. Our primary aim was to determine if
our approach would generate clinically relevant predictive values.
Our secondary aim was to determine if our modelling better
identified YORA. We demonstrate that clinically informative RA
risk prediction is possible and that the risk of younger and older
onset RA can be predicted using information on HLA and
smoking status, respectively.
Materials and Methods
Ethics Statement
All participants in WTCCC and UKRAGG were recruited
after providing informed consent. UKRAGG was approved by the
North West Multi-Centre Research Ethics Committee (MREC
99/8/84). Authors gained written permission and approval from
WTCCC to undertake this work in the publically available
WTCCC1 collections.
Study Populations
The WTCCC dataset contains SNP data on 1,999 RA cases
and 3,004 controls [28]. Controls were obtained from the 1958
British Birth Cohort and UK Blood Services. Genotyping was
performed on the Affymetrix GeneChip 500k Mapping Array Set.
Quality control (QC) procedures were undertaken excluding
individuals with ,97% SNP call rates, high heterozygosity, non-
European ancestry or relatedness, discordance between genotype
and phenotype data and duplicate samples. In the post-QC dataset
information was available on 490,031 SNP markers; the total
genotyping rate was 1.00. Two- or four-digit resolution HLA-
DRB1 tissue typing data were available on 1,837 cases and 1,647
controls.
The UKRAGG dataset contains SNP data on 5,024 RA cases
and 4,281 controls from 6 UK centres [29]. Genotyping was
performed using the Sequenom platform. Four hundred and
four SNPs were genotyped over 8 staggered plexes; for each plex
separate QC was undertaken excluding individuals and SNPs
with ,90% data present. In the post-QC dataset total
genotyping rates were 0.73 owing to systematic differences in
samples run on each plex. Two- or four-digit resolution HLA-
DRB1 tissue typing data were available on 3,420 cases and 1,500
controls.
Both datasets contained cases fulfilling the 1987 ACR classifi-
cation criteria for RA [30]. HLA-DRB1 tissue typing was
undertaken (at two-digit or four-digit resolution) at individual
centres, using commercially available semiautomated polymerase
chain reaction-sequence-specific oligonucleotide probe (PCR-
SSOP) typing techniques (or research assays based on PCR-SSOP
linear array technology) [29]. Two-digit typing includes the allele
group (Field 1) only; four-digit typing includes both the allele
group and the allele subtype encoding a specific HLA protein
(Field 2) (http://hla.alleles.org/nomenclature/naming.html).
Author Summary
Rheumatoid arthritis (RA) is a common, incurable disease
with major individual and health service costs. Preventing
its development is therefore an important goal. Being able
to predict who will develop RA would allow researchers to
look at ways to prevent it. Many factors have been found
that increase someone’s risk of RA. These are divided into
genetic and environmental (such as smoking) factors. The
risk of RA associated with each factor has previously been
reported. Here, we demonstrate a method that combines
these risk factors in a process called ‘‘prediction modelling’’
to estimate someone’s lifetime risk of RA. We show that
firstly, our prediction models can identify people with very
high-risks of RA and secondly, they can be used to identify
people at risk of developing RA at a younger age.
Although these findings are an important first step
towards preventing RA, as only a minority of people
tested had substantially increased disease risks our models
could not be used to screen the general population.
Instead they need testing in people already at risk of RA
such as relatives of affected patients. In this context they
could identify enough numbers of high-risk people to
allow preventive methods to be evaluated.
Predicting Rheumatoid Arthritis
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We undertook prediction modelling in seropositive cases and
controls with HLA-DRB1 tissue typing data available with or
without additional SNP and smoking data (as most replicated risk
loci are for seropositive RA and genetic risk is dominated by HLA)
[4], [31]. The final cohorts comprised 1,516 cases and 1,647
controls from WTCCC and 2,623 cases and 1,500 controls from
UKRAGG (Table 1).
Prediction Modelling Overview
Our modelling was performed within the R package, REGENT
(Risk Estimation for Genetic and Environmental Traits), devel-
oped within our unit. This program incorporates published gene-
environment risk factor and disease statistics to categorise risk
using a confidence interval (CI)-based approach within a simulated
population. The methodology underlying REGENT has previ-
ously been described in detail [32], [33].
Genetic and environmental risk factors for input into REGENT
are selected from the literature. Genetic risk factors require allelic
ORs, allele frequencies, and sample sizes from relevant studies, in
order to estimate precision. Environmental risk factors require
ORs, standard errors and the proportion of the population
exposed to the risk factor. Data on these risk factors are entered
into REGENT as summary statistic input files, which are
processed in two stages: the first develops the prediction model
and the second runs the prediction model in real life data.
In the first stage REGENT simulates a population-distribution
of disease risk. Risk profiles are simulated based on the frequency
of each risk factor in the general population. Summary ORs for
each risk profile are generated through combining the ORs for
each genetic and environmental risk factor in a multiplicative
model that assumes risk factor independence. CIs are generated
using information on the variability of genetic risk factors (derived
from the sample size of the risk variant discovery cohort) and
environmental risk factors (standard error of the effect size). Each
simulated risk profile’s OR is initially calculated relative to a
profile with no risk factors present; these are subsequently adjusted
to ensure correct disease prevalence in the population, assigning a
risk profile with a mean OR as having a baseline risk of 1.0. CIs
are used to classify risk profiles into four risk categories (reduced,
average, elevated and high-risk). Starting with the risk profile of
baseline risk (OR=1.0), any risk profile whose CI overlaps with
this baseline CI is classified as being of average-risk (as this profile
is not statistically different from baseline). Any risk profile whose
CI resides fully below the baseline CI is classified as reduced-risk.
Profiles with CIs above the baseline CI are classified as elevated-
risk. Furthermore, a high-risk group is determined by profiles
whose CIs reside completely above the CI of the first risk profile
classified as elevated-risk. An example of how this process is
undertaken in a simplified model using 3 SNPs is provided in
Figure S1.
In the second stage REGENT applies this simulated population
profile to individual level data. Genotypes and environmental risk
factor exposure data on each individual in the dataset of interest
(WTCCC and UKRAGG) are entered into REGENT, which
generates two measures of disease risk. Firstly, each individual’s
summary OR (95% CI) for RA is calculated (relative to the
baseline individual with an OR of 1.0); as with the simulated
population, risk factors are combined in a multiplicative model.
This summary OR informs the individual of their risk of
developing RA. Secondly, each individual is assigned a risk
category for RA. This is undertaken through comparing the CI of
each individual’s summary OR to those of the simulated risk
distribution in the same manner as described in stage 1. This risk
category informs an individual whether they are at an increased or
reduced risk of disease, relative to the average person in the
general population.
Prediction Model Components Identified from Meta-
Analyses
Genetic Risk Factors. We identified genetic susceptibility
variants for potential inclusion in our prediction modelling from
two large, recently published meta-analyses [34], [35]. We sought
to include only susceptibility alleles attaining genome-wide
significance (PGWAS,5610
28); this ensured that the alleles
modelled were replicated RA genetic risk factors. These comprised
15 four-digit and 10 two-digit HLA-DRB1 alleles and 35 non-HLA
SNPs.
Environmental Risk Factor. We included the environmen-
tal risk factor smoking in our modelling. Other factors proposed to
influence RA risk such as alcohol were not included: firstly the
evidence underlying these is uncertain, with associations often
present in case-control and not cohort studies [36] and secondly
Table 1. Clinical characteristics of WTCCC/UKRAGG cases and controls included in modelling.
WTCCC UKRAGG
RA (n=1,516) Controls (n =1,647) RA (n =2,623) Controls (n =1,500)
Gender Female 1,151 (76.0) 739 (50.0) 1,868 (71.2) 890 (59.9)
RA Characteristics RF+ 1,452 (96.1) - 2,385 (93.1) -
ACPA+ 1,061 (86.5) - 1,508 (84.8) -
Mean Age Of Onset (95% CI) 45.3 (44.6–46.1) - 48.0 (47.5–48.6) -
Erosive Disease 1,009 (71.1) - 830 (69.7) -
Nodules - - 859 (38.3) -
Smoking Status Male Ever-Smokers 231 (80.5)a 422 (57.1)a 417 (78.8)a 149 (46.3)a
Female Ever-Smokers 552 (58.3)b 425 (57.7)b 758 (55.9)b 238 (39.3)b
Data are number (%) unless otherwise stated. The following data are missing from WTCCC: gender in 2 cases and 169 controls; RF status in 5 cases; ACPA status in 290
cases; age of onset missing/inaccurate in 63 cases; erosive status in 96 cases; smoking status in 76 male cases, 204 female cases and 3 female controls. The following
data are missing from UKRAGG: gender in 14 controls; RF status in 60 cases; ACPA status in 844 cases; age of onset missing/inaccurate in 93 cases; erosive status in 1,432
cases; nodular status in 378 cases; smoking status in 226 male cases, 513 female cases, 274 male controls and 284 female controls.
a =% of males that are ever smokers;
b =% of females that are ever smokers.
doi:10.1371/journal.pgen.1003808.t001
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detailed data on non-smoking risk factors were not captured in
WTCCC and UKRAGG.
We used published ORs from the most recent meta-analysis
evaluating smoking as an RA risk factor [5]. In this meta-analysis
ever-smoking was a significant risk for seropositive RA in males
only (OR 3.02; 95% CI 2.35–3.88) with a substantially smaller and
non-significant (CIs contain 1) impact seen in females (OR 1.34;
95% CI 0.99–1.80). We therefore hypothesized that smoking
would not improve prediction in women (confirmed in preliminary
analyses; Table S1). As a result only males were evaluated in our
modelling incorporating ever-smoking.
Although smoking interacts with the shared epitope we did not
factor this into our modelling. This is because studies reporting
summary ORs for this interaction [6], [29], [37], [38] have
marked heterogeneity between them; therefore using meta-analysis
techniques to obtain pooled ORs for shared epitope-smoking
status combinations would be inaccurate and thus inappropriate.
Examples of this heterogeneity include: (1) studies reporting risks
stratified by different smoking levels, which would require an
inverse variance fixed-effects model to obtain common ORs for all
smokers within studies in addition to a random-effects model to
estimate pooled ORs across studies; (2) two studies classifying the
shared epitope at two-digit resolution, thus incorporating non-
shared epitope alleles [6], [37]; (3) two studies not including all
known shared epitope alleles [29], [38].
Prediction Model Component Availability in WTCCC and
UKRAGG
Two-digit or four-digit HLA-DRB1 tissue typing data were
available in all evaluated individuals. In WTCCC 1,342 seropos-
itive cases, 966 ACPA-positive cases and 1,126 controls had four-
digit resolution data available on both alleles; 29 seropositive cases,
14 ACPA-positive cases and 159 controls had two-digit resolution
data available on both alleles; 145 seropositive cases, 81 ACPA-
positive cases and 362 controls had mixed-digit resolution data
(one HLA-DRB1 allele known at four-digit and the other at two-
digit resolution) available. In UKRAGG 1,534 seropositive cases,
1,108 ACPA-positive cases and 735 controls had four-digit
resolution data available on both alleles; 312 seropositive cases,
66 ACPA-positive cases and 205 controls had two-digit resolution
data available on both alleles; 777 seropositive cases, 334 ACPA-
positive cases and 560 controls had mixed-digit resolution data
available.
We excluded 4 SNPs attaining PGWAS in the meta-analysis for
the following reasons: 1 (rs11676922) was in high linkage
disequilibrium (r2.0.9; HapMap release 22 CEU population
panel) [39] with another (rs10865035) – in this case the latter SNP
was included due to a previous association with RA – and 3 SNPs/
proxy SNPs were unavailable (rs10488631, rs6859219 and
rs934734 in UKRAGG; rs6822844, rs874040 and rs951005 in
WTCCC). Eleven and two proxy SNPs were used in WTCCC
and UKRAGG respectively (Table S2) [39].
Data on ever-smoking status were available in 287 male cases
and 739 male controls in WTCCC and 529 male cases and 322
male controls in UKRAGG.
Final Prediction Models
To examine the contribution of each gene-environment
component to prediction we constructed several models. These
comprised a SNP model (with 31 SNPs), an HLA model (10 two-
digit and 15 four-digit HLA-DRB1 alleles), an HLA-SNP model
(combining HLA and SNP model components), an HLA-smoking
model (combining HLA-DRB1 alleles with ever-smoking status)
and an HLA-SNP-smoking model (combining HLA-DRB1 alleles,
28 SNPs and ever-smoking status). Only the 28 SNPs present in
both WTCCC and UKRAGG were incorporated in the last
model. The latter two models, which included smoking, were
evaluated in males only.
The decision to combine two-digit and four-digit HLA-DRB1
alleles in the HLA model was undertaken to avoid removing the
substantial number of individuals with mixed resolution typing.
Preliminary analyses confirmed the validity of this approach with
no significant differences seen in the discriminative abilities of
HLA models incorporating (1) two-digit alleles only; (2) four-digit
alleles only and (3) a mixed resolution of alleles (Table S3). Within
our mixed resolution modelling the risks for each HLA allele were
included only once per individual at the highest resolution at
which they were known.
Only individuals with available data on relevant risk factors
were included in models incorporating those risk factors.
Therefore only males with available smoking data were included
in the HLA-smoking and HLA-SNP-smoking models. Similarly
only individuals with data available on the modelled SNPs could
be included in the HLA-SNP and HLA-SNP-smoking models.
Owing to missing data the number of individuals evaluated in each
prediction model fell as more risk factors were included (Figure 1).
Statistical Analyses
Evaluating Dataset Validity. To compare the representa-
tiveness of our datasets to published RA populations we
summarised clinical features of cases and controls (Table 1) and
calculated effect allele frequencies and allelic ORs (95% CIs)
(Tables 2 and 3). For the HLA-DRB1 allele case-control association
analysis (Table 2) the two-digit resolution allele results included
both individuals with two-digit resolution typing and collapsed
four-digit resolution typing. This approach was undertaken due to
the small number of individuals with two-digit typing data in
WTCCC/UKRAGG. The meta-analysis from which we obtained
our risk alleles had almost identical allele frequencies when
comparing two-digit alleles and four-digit alleles collapsed to two-
digit resolution [35]; comparing our datasets to the meta-analysis
findings in this manner was therefore appropriate.
Comparing Model Classification Abilities. To evaluate
the ability of each model to correctly classify disease status we
constructed receiver operating characteristic (ROC) curves and
measured the AUC; this is established methodology in determin-
ing genetic classification test efficacy [40], [41]. Higher AUCs
indicate better classification. An AUC.0.5 signifies some
discriminative ability; a perfect classifier has an AUC of 1. AUCs
were calculated and compared using DeLong’s method [42]
performed within the R package, pROC [43].
Comparing Model Generated Risk Distributions. The
risk distributions for cases and controls under each model were
compared by plotting the logarithmic OR for seropositive RA for
each individual ordered by risk.
Calculating Lifetime Risk of RA. Due to the low preva-
lence of RA [44], ORs approximate relative risks [45]. Therefore
to calculate lifetime risks of seropositive RA we multiplied
published lifetime risks by the summary OR for RA generated
by our prediction models. As UK lifetime risks of RA are unknown
we used estimates from a large US cohort study (2.4% for women;
1.1% for men) [46].
Evaluating YORA Prediction. The role of HLA, SNPs
and ever-smoking status in determining age of RA onset was
evaluated using individual-level OR outputs from the REGENT
models in a Cox univariate analysis with gender, smoking status
and smoking status-gender interaction used as covariates. Factors
indicated as likely predictors of age of onset were then examined
Predicting Rheumatoid Arthritis
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simultaneously in a multivariate analysis incorporating backward
elimination of non-significant factors (P.0.05). We found no
evidence of a ‘‘gender-smoking interaction’’ effect on the age of
RA onset in either dataset (WTCCC P=0.0823 and UKRAGG
P=0.8369; Table 4). This excluded a significant influence of
gender on the relationship between smoking and the age at which
RA developed. We therefore included both sexes when evaluating
smoking’s effect on the age of onset. Proportional hazards
assumptions were verified using visual inspection of log-log plots
[47]. To further demonstrate associations between significant
factors and age of onset we constructed Kaplan-Meier estimates of
the cumulative risk for cases, stratified by REGENT risk
categorisation from the relevant models, alongside the presence/
absence of other risk factors. We used a Cox multivariate
approach to establish which four-digit HLA-DRB1 alleles influ-
enced age of onset (fitting all alleles simultaneously using stepwise
selection, removing non-significant alleles from the final model).
All time to event analyses were performed using SAS version 9.3
(SAS Institute, Cary, NC).
Separate Analyses for ACPA-Positive RA
We undertook modelling separately for seropositive (RF and/or
ACPA present) RA and ACPA-positive RA since HLA-DRB1
allelic ORs were obtained from a meta-analysis evaluating
ACPA-positive RA [35], and the shared epitope alleles, non-
HLA SNPs and smoking predominantly associate with ACPA-
positive disease [4], [48–50]. We therefore hypothesised our
modelling would perform better for ACPA-positive RA. As this
was confirmed in the risk categorisation results we restricted
further analyses (AUC and lifetime risk calculations, examining
modelling associations with age of RA onset) to ACPA-positive
RA.
Results
Dataset Validity
Genetic Risk Factors. In both WTCCC and UKRAGG the
effect allele frequencies and ORs for seropositive RA were
generally similar to published data (Tables 2 and 3). Exceptions
occurred at the four-digit HLA-DRB1 alleles *04:08 and *15:01
(absent from controls in WTCCC and UKRAGG respectively), at
*01:01, *11:01, *11:04, *13:01 and *15:01 in WTCCC and *08:01
in UKRAGG (significantly lower allele frequencies in controls
than expected). The absence of *04:08 in controls was probably a
chance finding since it has a frequency of 0.005. The remaining
discrepancies resulted from lower four-digit tissue typing rates for
these alleles in controls, which were more often typed at two-digits,
compared with cases. Although this could introduce bias,
Figure 1. Number of individuals evaluated in each prediction model.
doi:10.1371/journal.pgen.1003808.g001
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especially in the context of case-control association analyses, we do
not consider it significantly affected our prediction modelling
because these alleles were incorporated in our models at both two-
digit and four-digit resolution (in most cases in the reference meta-
analysis the two-digit alleles had similar allele frequencies and ORs
compared with the four-digit alleles) and our risks were obtained
from an external source [35].
SNP discrepancies occurred at rs3761847 in WTCCC and
rs26232 and rs540386 in UKRAGG, which had ORs in the
opposite direction to published results although the dataset and
meta-analysis 95% CI’s overlapped for two SNPs. Additionally the
minor allele frequencies (MAFs) in controls were similar to those
expected. These discrepancies probably represent normal varia-
tion as opposed to systematic genotyping differences.
Most HLA-DRB1 alleles had significant associations with RA,
with only 4 (16%) alleles in WTCCC and 3 (12%) alleles in
UKRAGG having 95% CIs containing 1.0. A substantial propor-
tion of SNPs – 13 (42%) in WTCCC and 15 (48%) in UKRAGG –
had 95% CIs containing 1.0 reflecting their modest effect sizes,
which required large discovery cohort sizes for detection.
Environmental Risk Factors. The ORs for seropositive RA
in ever-smokers were 3.10 (95% CI 2.22–4.37) in WTCCC and
4.32 (95% CI 3.16–5.92) in UKRAGG for males and 1.02 (95%
CI 0.84–1.25) in WTCCC and 1.96 (95% CI 1.61–2.40) in
UKRAGG for females. The meta-analysis gender discrepancy
surrounding the effect of ever-smoking on RA risk [5] was
therefore mirrored in our datasets supporting the inclusion of only
males in our smoking models.
Risk Prediction
Risk Categorisation. As hypothesized, our modelling more
accurately categorised ACPA-positive RA as high-risk compared
with seropositive RA (Figure 2 and Table S4). The HLA model
provided most prediction in both datasets, classifying approxi-
mately one third of ACPA-positive RA as high-risk and two thirds
of controls reduced-risk. Although the SNP model provided some
prediction it classified most individuals as average-risk, reflecting
the overlapping CIs generated by including many risk factors of a
small effect size.
In WTCCC, the full genetic (HLA-SNP) model performed
slightly better than HLA alone. Additional smoking data conferred
subtle improvements in categorisation; this is particularly seen with
the HLA-SNP-smoking model, which classified over half of
ACPA-positive RA elevated/high-risk and 59% of controls
reduced-risk.
In UKRAGG the addition of SNPs to HLA alleles increased the
average-risk group size with no clear predictive benefits. The
incorporation of smoking substantially improved prediction: the
Table 2. Classical HLA-DRB1 allele frequencies and their association with seropositive RA in WTCCC and UKRAGG.
Published Meta-Analysis [35] WTCCC UKRAGG
HLA-DRB1 Allele OR (95% CI) MAF Co MAF Ca OR (95% CI) MAF Co MAF Ca OR (95% CI) MAF Co MAF Ca
*01 1.30 (1.21–1.40) 0.113 0.145 1.53 (1.31–1.78) 0.104 0.151 1.27 (1.11–1.45) 0.121 0.149
*01:01 1.38 (1.28–1.50) 0.097 0.133 5.88 (4.62–7.55) 0.026 0.136 1.25 (1.06–1.47) 0.081 0.099
*03 0.59 (0.54–0.64) 0.128 0.082 0.67 (0.58–0.78) 0.148 0.105 0.76 (0.67–0.86) 0.159 0.125
*03:01 0.59 (0.54–0.64) 0.128 0.082 0.65 (0.55–0.76) 0.145 0.099 0.44 (0.37–0.51) 0.130 0.061
*04 3.71 (3.49–3.93) 0.174 0.450 2.90 (2.59–3.24) 0.213 0.439 3.19 (2.86–3.56) 0.184 0.419
*04:01 4.14 (3.86–4.44) 0.104 0.309 2.93 (2.57–3.35) 0.124 0.293 3.00 (2.63–3.42) 0.111 0.272
*04:04 3.17 (2.83–3.54) 0.036 0.091 1.86 (1.52–2.28) 0.052 0.092 2.56 (2.08–3.18) 0.039 0.093
*04:05 2.31 (1.77–3.01) 0.007 0.012 2.01 (1.12–3.73) 0.006 0.012 2.61 (1.34–5.58) 0.004 0.010
*04:08 5.48 (4.11–7.30) 0.005 0.017 -a 0.000 0.021 2.78 (1.70–4.76) 0.007 0.018
*07 0.49 (0.45–0.54) 0.133 0.064 0.48 (0.41–0.56) 0.154 0.080 0.54 (0.46–0.62) 0.142 0.081
*07:01 0.49 (0.45–0.54) 0.133 0.064 0.41 (0.35–0.49) 0.154 0.070 0.37 (0.32–0.44) 0.140 0.057
*08 0.41 (0.34–0.50) 0.029 0.013 0.39 (0.24–0.62) 0.022 0.009 0.30 (0.20–0.44) 0.029 0.009
*08:01 0.34 (0.26–0.44) 0.019 0.009 0.27 (0.13–0.53) 0.014 0.004 0.69 (0.33–1.46) 0.005 0.003
*10 2.53 (2.04–3.14) 0.008 0.020 1.97 (1.11–3.59) 0.006 0.012 1.75 (1.04–3.07) 0.007 0.012
*10:01 2.53 (2.04–3.14) 0.008 0.020 1.97 (1.11–3.59) 0.006 0.012 1.48 (0.85–2.67) 0.006 0.009
*11 0.48 (0.43–0.54) 0.094 0.039 0.50 (0.39–0.64) 0.064 0.033 0.42 (0.34–0.53) 0.065 0.028
*11:01 0.44 (0.38–0.52) 0.061 0.028 0.80 (0.55–1.14) 0.023 0.018 0.33 (0.23–0.47) 0.030 0.010
*11:04 0.15 (0.10–0.23) 0.024 0.008 0.79 (0.41–1.49) 0.008 0.006 0.38 (0.15–0.91) 0.005 0.002
*13 0.33 (0.30–0.37) 0.114 0.044 0.41 (0.33–0.50) 0.098 0.042 0.46 (0.38–0.55) 0.084 0.040
*13:01 0.28 (0.24–0.33) 0.061 0.021 0.77 (0.54–1.08) 0.026 0.020 0.42 (0.29–0.59) 0.027 0.011
*13:02 0.29 (0.23–0.38) 0.027 0.012 0.59 (0.38–0.90) 0.020 0.012 0.27 (0.18–0.42) 0.023 0.006
*14 0.50 (0.40–0.62) 0.025 0.012 0.51 (0.34–0.76) 0.024 0.013 0.45 (0.31–0.65) 0.023 0.010
*14:01 0.46 (0.36–0.59) 0.022 0.011 0.43 (0.28–0.66) 0.024 0.011 0.67 (0.34–1.33) 0.006 0.004
*15 0.59 (0.54–0.64) 0.142 0.092 0.63 (0.53–0.75) 0.128 0.084 0.60 (0.53–0.70) 0.146 0.093
*15:01 0.57 (0.53–0.62) 0.136 0.089 1.09 (0.87–1.37) 0.051 0.055 -a 0.000 0.025
All alleles attained genome-wide significance in the published meta-analysis; MAF=minor allele frequency; Co = controls; Ca =Cases;
a =OR incalculable due to no allele copies in the control group.
doi:10.1371/journal.pgen.1003808.t002
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HLA-SNP-smoking model classified 38% ACPA-positive RA vs.
3% controls as high-risk and 70% controls vs. 18% ACPA-positive
RA as reduced-risk.
The general trend of improved prediction through modelling
increasing numbers of risk factors is highlighted by the ratios of
the percentage of ACPA-positive cases to controls classified
high-risk by each model. In WTCCC these comprise 3.4 for the
SNP model, 3.8 for the HLA model, 5.8 for the HLA-SNP
model, 4.8 for the HLA-smoking model and 6.0 for the HLA-
SNP-smoking model. Similarly, the ratios of the percentage of
controls to ACPA-positive cases classified reduced-risk in
WTCCC comprise 2.3 for the SNP model, 2.4 for the HLA
model, 3.4 for the HLA-SNP model, 4.0 for the HLA-smoking
model and 4.7 for the HLA-SNP-smoking model. Similar
findings were present in UKRAGG.
AUC Assessments. In WTCCC AUCs for the SNP, HLA,
HLA-SNP, HLA-smoking and HLA-SNP-smoking models in
discriminating between ACPA-positive RA and controls com-
prised 0.660 (95% CI 0.638–0.681), 0.764 (95% CI 0.746–0.782),
0.796 (95% CI 0.779–0.813), 0.813 (95% CI 0.784–0.841) and
0.837 (95% CI 0.810–0.865), respectively (Figure 3). Significant
differences in AUCs were observed between all three genetic
models: SNP and HLA models P,0.0001; HLA and HLA-SNP
models P=0.0118. Smoking data significantly improved discrim-
Table 3. Non-HLA RA susceptibility SNP allele frequencies and their association with seropositive RA in WTCCC and UKRAGG.
Published Meta-Analysis [34] WTCCC UKRAGG
Loci SNP MAFa OR MAF Ca/Co OR (95% CI) MAF Ca/Co OR (95% CI)
PTPN22 rs2476601 0.10 1.94 (1.81–2.08) 0.18/0.10 2.02 (1.73–2.36) 0.16/0.10 1.60 (1.38–1.85)
TNFAIP3 rs6920220 0.22 1.22 (1.16–1.29) 0.27/0.23 1.26 (1.12–1.41) 0.25/0.21 1.29 (1.15–1.44)
ANKRD55, IL6ST rs6859219 0.21 0.78 (0.72–0.85) 0.17/0.20 0.80 (0.70–0.91) - -
CD40 rs4810485 0.25 0.85 (0.80–0.90) 0.22/0.24 0.87 (0.77–0.99) 0.22/0.25 0.83 (0.74–0.93)
CTLA4 rs3087243 0.44 0.87 (0.83–0.91) 0.43/0.44 0.95 (0.86–1.06) 0.43/0.47 0.86 (0.78–0.94)
TNFAIP3 rs5029937 0.04 1.40 (1.24–1.58) 0.06/0.04 1.58 (1.24–2.02) 0.05/0.04 1.39 (1.06–1.82)
IL2RA rs706778 0.40 1.14 (1.09–1.20) 0.46/0.42 1.17 (1.05–1.29) 0.43/0.40 1.13 (1.02–1.25)
RBPJ rs874040 0.30 1.14 (1.08–1.20) - - 0.33/0.31 1.11 (1.00–1.23)
TRAF1, C5 rs3761847 0.43 1.13 (1.08–1.18) 0.45/0.46 0.96 (0.87–1.07) 0.46/0.43 1.12 (1.01–1.24)
STAT4 rs7574865 0.22 1.16 (1.10–1.23) 0.21/0.19 1.12 (0.99–1.27) 0.25/0.22 1.18 (1.05–1.32)
SPRED2 rs934734 0.49 1.13 (1.08–1.19) 0.53/0.51 1.11 (1.00–1.23) - -
CCR6 rs3093023 0.43 1.13 (1.08–1.19) 0.42/0.40 1.10 (0.99–1.22) 0.47/0.44 1.16 (1.05–1.28)
PXK rs13315591 0.09 1.29 (1.17–1.43) 0.10/0.09 1.11 (0.94–1.32) 0.08/0.07 1.10 (0.91–1.33)
C5orf30 rs26232 0.32 0.88 (0.84–0.93) 0.34/0.40 0.78 (0.70–0.86) 0.31/0.31 1.03 (0.92–1.14)
CCL21 rs951005 0.16 0.84 (0.78–0.90) - - 0.13/0.15 0.86 (0.75–0.99)
REL rs13031237 0.37 1.13 (1.07–1.18) 0.45/0.43 1.07 (0.96–1.18) 0.41/0.37 1.22 (1.10–1.35)
AFF3 rs10865035 0.47 1.12 (1.07–1.17) 0.50/0.46 1.19 (1.07–1.31) 0.48/0.45 1.16 (1.05–1.27)
PRKCQ rs4750316 0.19 0.87 (0.82–0.92) 0.16/0.20 0.77 (0.67–0.87) 0.18/0.19 0.89 (0.79–1.00)
IRF5 rs10488631 0.11 1.19 (1.10–1.28) 0.12/0.10 1.22 (1.04–1.44) - -
TNFRSF14 rs3890745 0.32 0.89 (0.85–0.94) 0.29/0.32 0.85 (0.76–0.95) 0.32/0.33 0.97 (0.88–1.08)
CD2, CD58 rs11586238 0.24 1.13 (1.07–1.19) 0.26/0.24 1.08 (0.96–1.21) 0.26/0.26 1.05 (0.93–1.17)
BLK rs2736340 0.25 1.12 (1.07–1.18) 0.27/0.25 1.10 (0.98–1.24) 0.26/0.24 1.14 (1.01–1.28)
CD28 rs1980422 0.24 1.12 (1.06–1.18) 0.25/0.23 1.13 (1.01–1.28) 0.26/0.23 1.15 (1.03–1.30)
PRDM1 rs548234 0.33 1.10 (1.05–1.16) 0.36/0.34 1.11 (1.00–1.23) 0.35/0.35 1.00 (0.90–1.10)
CCL21 rs2812378 0.34 1.10 (1.05–1.16) 0.38/0.34 1.17 (1.05–1.30) 0.36/0.35 1.02 (0.92–1.13)
PTPRC rs10919563 0.13 0.88 (0.82–0.94) 0.11/0.13 0.82 (0.70–0.95) 0.13/0.14 0.93 (0.80–1.07)
KIF5A, PIP4K2C rs1678542 0.38 0.91 (0.87–0.96) 0.34/0.37 0.86 (0.77–0.95) 0.35/0.35 0.97 (0.88–1.07)
TRAF6 rs540386 0.14 0.88 (0.83–0.94) 0.11/0.13 0.90 (0.77–1.05) 0.14/0.13 1.03 (0.89–1.19)
FCGR2A rs12746613 0.12 1.13 (1.06–1.21) 0.14/0.12 1.17 (1.01–1.36) 0.14/0.11 1.26 (1.08–1.46)
TAGAP rs394581 0.30 0.91 (0.87–0.96) 0.28/0.30 0.92 (0.82–1.03) 0.28/0.29 0.94 (0.84–1.05)
TNFAIP3 rs10499194 0.27 0.91 (0.87–0.96) 0.25/0.27 0.90 (0.80–1.01) 0.26/0.28 0.90 (0.81–1.00)
IL2, IL21 rs6822844 0.18 0.90 (0.84–0.95) - - 0.15/0.19 0.80 (0.71–0.91)
IL2RA rs2104286 0.27 0.92 (0.87–0.97) 0.24/0.27 0.85 (0.76–0.96) 0.25/0.26 0.94 (0.84–1.04)
IL2RB rs3218253 0.26 1.09 (1.03–1.15) 0.29/0.25 1.22 (1.09–1.37) 0.29/0.27 1.09 (0.98–1.22)
SNPs are ordered by significance (most significant by PGWAS listed first); all alleles attained genome-wide significance in the published meta-analysis; Ca = Cases;
Co = Controls; MAF =Minor Allele Frequency;
a =MAF in controls.
doi:10.1371/journal.pgen.1003808.t003
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ination with differences observed between HLA and HLA-
smoking model AUCs (P=0.0051) and HLA-SNP and HLA-
SNP-smoking model AUCs (P=0.0120).
In UKRAGG AUCs for the SNP, HLA, HLA-SNP, HLA-
smoking and HLA-SNP-smoking models in discriminating be-
tween ACPA-positive RA and controls comprised 0.617 (95% CI
0.577–0.656), 0.748 (95% CI 0.731–0.765), 0.756 (95% CI 0.723–
0.790), 0.813 (95% CI 0.782–0.845) and 0.857 (95% CI 0.804–
0.910), respectively (Figure 3). The HLA model had significantly
better discrimination than the SNP model (P,0.0001). Combined
SNP and HLA data did not improve discrimination with no
differences observed between AUCs for the HLA and HLA-SNP
models (P=0.665) or the HLA-smoking and HLA-SNP-smoking
models (P=0.1671). Additional smoking information significantly
improved modelling discrimination with significant differences
observed between HLA and HLA-smoking model AUCs
(P=0.0003).
An overview of the main findings for each of the 5 prediction
models, alongside the differences between them is provided in
Figure S2.
Risk Distributions. In both datasets the HLA model
provided most risk prediction generating substantially higher and
lower ORs for RA in cases and controls respectively compared
with the SNP model (Figure 4).
In WTCCC the addition of other risk factors to the HLA-DRB1
alleles resulted in further small incremental increases in ORs for
RA in cases; a less pronounced reduction in risk was seen in
controls.
Table 4. Relationship between modelling components and age of RA onset.
WTCCC UKRAGG
Univariate Analysisc Univariate Analysis Multivariate Analysis
Modelling Component
No. Cases
Examined P-Value
Hazard Ratio
(95% CI)
No. Cases
Examined P-Value
Hazard Ratio
(95% CI) P-Value
Hazard ratio
(95% CI)
HLAa,b 1022 ,0.0001 1.034 (1.018–1.050) 1456 0.0004 1.025 (1.011–1.038) 0.0003 1.026 (1.012–1.040)
SNPa 1022 0.1804 1.043 (0.981–1.110) 284 0.294 1.075 (0.939–1.230) - -
Genderb 1021 0.2157 0.914 (0.792–1.054) 1456 0.0107 0.864 (0.722–0.967) 0.0465 0.885 (0.786–0.998)
Smokingb 962 0.1301 0.902 (0.789–1.031) 1361 0.0009 0.830 (0.743–0.927) 0.0041 0.848 (0.757–0.949)
Gender-Smoking Interactionb 961 0.0823 0.870 (0.744–1.018) 1361 0.009 0.846 (0.746–0.959) 0.8369 -
a =HLA and SNP variables represent the summary OR scores generated by the models incorporating HLA and SNP data respectively;
b = variables included in UKRAGG multivariate model after variable pruning using backwards selection and model comparison with Akaike’s Information Criterion;
c = as only one parameter was significant in the WTCCC univariate analysis no multivariate model was fitted.
doi:10.1371/journal.pgen.1003808.t004
Figure 2. Risk categorisation of RA and controls by each prediction model. The y-axis on each graph refers to the proportion of cases/
controls in each risk category; cont = controls; sero+= seropositive RA; ACPA+=ACPA-positive RA.
doi:10.1371/journal.pgen.1003808.g002
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In UKRAGG the addition of SNPs to HLA data provided no
changes in case risk profiles, although a minority of controls had
lower ORs. Additional smoking data resulted in significantly
higher ORs for cases; only the HLA-SNP-smoking model clearly
generated lower risk profiles for controls.
Lifetime Risk Prediction. Evaluating risks using genetics
(HLA-SNP model) alone the highest risk WTCCC ACPA-positive
case had an OR for seropositive RA of 79; as a male his lifetime
risk was estimated at 86%. The highest risk control had an OR of
22; as a female her lifetime risk was estimated at 53%. Despite
such high individual odds only a relative minority had relevant
increased lifetime risks: using the same HLA-SNP model 49
(4.61%) ACPA-positive cases and 1 (0.07%) control had ORs for
seropositive RA.20 (lifetime risks .48% if female and .22% if
male) in WTCCC. In UKRAGG 9 (3.06%) ACPA-positive cases
and 1 (0.17%) control had ORs.20.
The HLA-SNP-smoking model identified the greatest propor-
tion of cases with substantially increased lifetime risks for RA. This
model identified 18 (7.53%) and 3 (3.75%) ACPA-positive male
cases to have ORs for seropositive RA.20 (lifetime risk .22%) in
WTCCC and UKRAGG respectively; no controls had ORs.20.
Younger Onset RA Prediction
In WTCCC the HLA model summary OR score was the only
significant predictor of age of RA onset (Table 4). The hazard ratio
(HR) was 1.034 (P,0.0001), which indicated that the hazard (the
rate at which RA occurred) was greater in individuals with higher
HLA derived ORs than those with lower ORs. Therefore a higher
HLA model generated risk score associated with RA occurring at a
faster rate and thus YORA. Conversely ever-smoking was
associated with older onset RA: the HR of 0.902 indicated a
smaller hazard (RA occurred at a slower rate) in ever-smokers
compared with never-smokers, although this was not significant
(P=0.1301).
In UKRAGG the HLA model summary OR score, gender and
smoking status were significant independent predictors of age of
Figure 3. Prediction model receiver operating characteristic curves. Panel A =WTCCC; Panel B =UKRAGG; ROCs calculated for discriminating
between ACPA-positive RA and controls; AUC= area under the curve. WTCCC model AUC comparisons: SNP versus HLA, P,0.0001; HLA versus HLA-
SNP, P= 0.0118; HLA-SNP versus HLA-Smoking, P=0.3327; HLA-Smoking versus HLA-SNP-Smoking, P=0.0001. UKRAGG model AUC comparisons: SNP
versus HLA, P,0.0001; HLA versus HLA-SNP, P=0.665; HLA-SNP versus HLA-Smoking, P= 0.0145; HLA-Smoking versus HLA-SNP-Smoking, P= 0.1671.
doi:10.1371/journal.pgen.1003808.g003
Figure 4. Prediction model generated risk profiles for ACPA-positive RA and controls. Panel A =WTCCC; Panel B =UKRAGG; the upper set
of lines for each model refer to RA cases; the lower set of lines refer to controls; OR= odds ratio.
doi:10.1371/journal.pgen.1003808.g004
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onset. An increasing HLA summary OR score associated with
YORA (P=0.0003, HR 1.026); ever-smoking (P=0.0041, HR
0.848) and male gender (P=0.0465, HR 0.885) associated with
older onset RA.
We considered that the non-significant relationship between
smoking and age of onset in WTCCC reflected a limited sample
size with our power to detect a 0.88 HR in the 962 WTCCC cases
approximately 51% compared with 65% for the 1,361 UKRAGG
cases. We therefore undertook a pooled analysis of both datasets
(incorporating an additional ‘‘study’’ variable to account for
dataset median age of onset differences). This confirmed that HLA
derived risk scores significantly associated with YORA (P,0.0001,
HR 1.030) and ever-smoking significantly associated with older
onset RA (P=0.0489, HR 0.889).
Kaplan-Meier curves of age of onset stratified by HLA model
risk categorisation further demonstrate the association of HLA risk
profiles with YORA (Figure 5) with cases classified high-risk
having significantly younger onset ages compared to those
classified reduced-risk. In WTCCC the difference in the median
time to RA (time point at which half the cases have developed RA)
was 3 years between those classed high- and reduced-risk (Log-
Rank= 11.43; P=0.0007). In UKRAGG a stronger association
was seen (Log-Rank= 27.33; P,0.0001) with a difference in
median time to RA onset between risk groups of 6 years. Further
stratification by ever-smoking status demonstrated a trend towards
an older onset age in ever-smokers. In WTCCC the median time
to onset difference between high-risk never-smokers and reduced-
risk ever-smokers was 7 years (Log-Rank= 14.42; P=0.0024); a
larger disparity was seen in UKRAGG with a difference of 12
years observed (Log-Rank= 46.2505; P,0.0001).
Examining which four-digit resolution HLA-DRB1 alleles
influenced onset age revealed significant associations between
age of onset and *03:01 (P=0.0313), *04:01 (P=0.0001), *04:08
(P=0.0032) and *13:02 (P=0.0097) in WTCCC and *04:01
(P,0.0001) and *04:04 (P=0.0243) in UKRAGG. Three of these
alleles (*04:01, *04:04 and *04:08) are shared-epitope alleles.
Discussion
We have demonstrated that predicting RA development is
possible with our prediction models able to identify individuals
with clinically relevant increased risks for seropositive RA. Our
modelling indicates that most prediction is provided by HLA-
DRB1 alleles and, to a lesser extent, smoking in males; non-HLA
susceptibility SNPs provide only minor predictive benefits. These
findings are consistent with the estimations of heritability variance
Figure 5. Kaplan-Meier curves: RA age of onset stratified by HLA model risk categorisation and smoking status. Panel A=WTCCC
Curves Stratified By Risk Categorisation; Panel B =UKRAGG Curves Stratified By Risk Categorisation; Panel C =WTCCC Curves Stratified By Risk
Categorisation and Ever-Smoking Status; Panel D=UKRAGG Curves Stratified By Risk Categorisation and Ever-Smoking Status; D= change in onset
age; Dm=maximum change in onset age across strata.
doi:10.1371/journal.pgen.1003808.g005
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conferred by different genetic components. We have also shown it
is possible to predict the age of RA onset, using information on
HLA and smoking to identify those at risk of younger and older
onset RA, respectively. Whilst our novel modelling approach,
which uses computer simulation-based categorisation alongside a
greater number of HLA alleles, significantly improves upon the
discriminative abilities of existing models [26], [27] it remains
unsuitable for population screening with only a minority at
significantly increased lifetime risks for RA.
Our approach provides some potential advantages over
existing RA prediction modelling [26], [27]. Firstly, by using a
simulated population to generate risk profiles we do not require
an entire population of real-life data to stratify risks. In contrast
existing approaches categorise wGRS scores using their Gauss-
ian distribution in control groups. Secondly, our CI-based
approach considers the precision with which risk factor effect
sizes are known when classifying risk; this prevents classifying
people high-risk if their risk is imprecisely known. Thirdly, our
models provide greater discrimination: the highest AUC for
existing clinical-genetic models in discerning ACPA-positive RA
from controls is 0.752; the highest AUC for our clinical-genetic
model is 0.857.
SNPs provided only minor improvements in prediction,
highlighting the limitations of genome-wide association study
(GWAS) derived data in this field. Although GWAS-established
SNPs have helped identify cellular pathways relevant to RA
pathogenesis [51] their modest effect sizes limit their predictive
utility. It has been proposed that the missing heritability of RA
may reflect the involvement of rare variants of large effect sizes or
structural variants [52]. Alternative genotyping technologies such
as next-generation sequencing may identify these variants,
although only loci with large effect sizes will substantially improve
prediction modelling.
Although individuals with clinically relevant increased lifetime
risks (such as 86%) for RA were identified there was, overall, only
a minority of individuals at a significantly elevated risk: 7% of
ACPA-positive individuals had lifetime risks of 22% or more when
evaluated using all available risk factors. Therefore despite high
AUCs our modelling is unsuitable for population level screening.
However, if its use was targeted to groups with a priori increased
risks, such as first degree relatives of RA probands [53–55], then a
substantially greater proportion of very high-risk individuals might
be identified.
Individuals classified high-risk by our HLA model were more
likely to develop RA at a younger age. This finding – mainly
attributable to the *04:01 allele – is supported by existing
literature. Hellier et al reported a higher frequency of *04 RA
associated alleles in YORA (present in 52% of 262 RA cases with
onset age ,60) compared with elderly onset RA (present in 37%
of 60 cases with onset age .60; P=0.045) [18]. Similarly, Wu et al
identified a significantly younger age of onset in Caucasian RA
patients carrying shared epitope encoding *04 alleles (P=0.0003)
[19]. Other studies report positive correlations between YORA
and shared epitope alleles [25], [56]. Our finding of ever-smoking
associating with older onset RA is less established. It has only been
examined in three relatively small studies, with contrasting
outcomes: one study reported a significant relationship between
smoking at disease onset and a younger onset age [57]; one
reported a younger onset age in current vs. never-smokers
(although ex-smokers had older onset RA in comparison to both
these groups) [58]; the final study found no association [59]. Our
findings – demonstrated in 2,323 individuals across two indepen-
dent datasets – are biologically plausible. As risk genotypes are
present from birth they can exert their effects on disease risk
throughout an individual’s lifetime; therefore possessing high-risk
HLA-DRB1 alleles predisposes to RA at a younger age. In contrast
the risk of RA increases as more cigarettes are smoked [60], [61]
and smokers are exposed to more cigarettes as they age; therefore
smokers are more likely to develop RA as they get older because
they have been exposed to more cigarettes and thus smoking
associates with older onset RA. This logic also explains why ever-
smoking associates with older onset RA in both men and women,
with heavy smoking a risk factor for RA in both genders [5]. We
were, however, unable to incorporate heavy smoking in our
prediction modelling due to a paucity of data on smoking pack-
years in WTCCC/UKRAGG.
We incorporated many genetic risk factors in our modelling but
included only one environmental risk factor, smoking. This reflects
uncertainty regarding relevant environmental risks alongside
limited environmental data within current genetic datasets.
Although many environmental factors are linked to RA their
associations are usually identified in case-control studies, which are
subject to multiple biases, rather than cohort studies. Examples
include alcohol consumption [36], parity [62], [63] and oral
contraceptive pill use [64]. Better characterisation of environmen-
tal risks will enhance predictive modelling.
Our modelling has several limitations. Firstly, WTCCC
participants were included in the meta-analyses that we
obtained our genetic risk loci data from; however WTCCC
comprised only a proportion of the meta-analyses datasets (20%
of the HLA meta-analysis; 29% of the SNP meta-analysis) and
our findings were independently replicated in UKRAGG.
Secondly, missing data meant the number of individuals
included in each model fell as more risk factors were included;
this is particularly seen in models incorporating smoking.
Thirdly, due to marked heterogeneity in published data on
gene-gene/gene-environment interactions we assumed indepen-
dence between these factors despite known interactions existing
between the shared epitope alleles and PTPN22 and smoking
[6], [7], [29], [37], [38].
Improving RA prediction requires better clarification of its
genetic and environmental risk factors. Identifying risk factors with
large effect sizes of known precision will most enhance prediction
modelling. This could be facilitated through fine-mapping studies
that better tag causal variants [65] alongside prospective cohort
studies examining environmental risk factors in RA cases
subdivided by ACPA status, with increasing evidence that risks
differ between these serological subsets [36], [66]. It is, however,
unlikely that identifying such risk factors will substantially increase
the proportion of individuals with clinically relevant high disease
risks. We therefore consider that prediction modelling requires
evaluation in a priori higher risk groups. In this context it may
identify sufficient numbers of very high-risk individuals, facilitating
a better understanding of pre-RA immunopathology and enabling
the assessment of primary prevention strategies.
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